Cancer Drug Firm Ducks Shareholder Suit Over $26M Offering
A putative class action lawsuit accusing GenVec Inc. of raising $26.2 million from shareholders to develop a pancreatic cancer treatment it knew to be ineffective was dismissed from a Maryland federal...To view the full article, register now.
Already a subscriber? Click here to view full article